Efficacy and Effectiveness of Antidepressants: Current Status of Research
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Background: This paper examines the current status of research on the efficacy and effectiveness of antidepressants. Methods: This paper reviews four meta-analyses of efficacy trials submitted to America’s Food and Drug Administration (FDA) and analyzes STAR*D (Sequenced Treatment Alternatives to Relieve Depression), the largest antidepressant effectiveness trial ever conducted. Results: Meta-analyses of FDA trials suggest that antidepressants are only marginally efficacious compared to placebos and document profound publication bias that inflates their apparent efficacy. These meta-analyses also document a second form of bias in which researchers fail to report the negative results for the pre-specified primary outcome measure submitted to the FDA, while highlighting in published studies positive results from a secondary or even a new measure as though it was their primary measure of interest. The STAR*D analysis found that the effectiveness of antidepressant therapies was probably even lower than the modest one reported by the study authors with an apparent progressively increasing dropout rate across each study phase. Conclusions: The reviewed findings argue for a reappraisal of the current recommended standard of care of depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the STAR-D trial, the largest naturalistic study of antidepressants so far conducted, the remission rate at one year for all participants taking antidepressants was 2.7% (108/4000), and 92.9% relapsed or dropped out (Pigott 2010).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Pigott 2010
In the citing paper
“Currently available antidepressant medications largely target monoamine pathways, but treatment of depression is only effective in about a third to a half of patients.1, 2”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [1]
In the citing paper
“current treatment of depression is only effective in about a third to a half of patients,1, 2”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [1]
In the citing paper
“In this study, 84 % of participants in this study answered in the affirmative to a question about whether they felt antidepressants had reduced their depression, a number well above that suggested by efficacy studies”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [26]
In the citing paper
“An understanding of users’ own experiences of antidepressant use is increasingly important in the context of growing doubts about the effectiveness of antidepressant treatment [5, 26], concerns about side effects [27] and withdrawal effects [28].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [26]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“recommendations for distinguishing between specific and nonspecific treatment effects, the first one being having an active placebo arm to reduce the likelihood of unblinding and thereby control the potential role of side effects in enhancing patients’ expectation of improvement. Real-World Effectiveness of Antidepres…”
BackgroundRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“p. 129] (table 2 ). 2 Table 2. Survival analysis by treatment step of patients who entered continuing care in remission T02 As mentioned earlier, STAR*D was designed to identify the best next-step treatment for the many patients who fail to get adequate relief from their initial SSRI trial. Due to the high study dropo…”
MethodKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
HARKing: Hypothesizing after the results are known
Kerr, N. L. (1998) · Personality and Social Psychology Review · doi:10.1207/s15327957pspr0203_4 · Cited by 1,989
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
The Existence of Publication Bias and Risk Factors for Its Occurrence
Dickersin, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440100097014 · Cited by 1,417
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“observed that early RCTs often enrolled hospitalized patients who were less responsive to placebo, whereas more recent trials typically enroll highly selected outpatients, contacted through mass media advertisements, who may be less severely depressed. In a meta-analysis of 75 RCTs published between 1981 and 2000, Wal…”
BackgroundSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“p. 739].The conclusion section of the research design article of STAR*D states: ‘STAR * D uses a randomized, controlled design to evaluate both the theoretical principles and clinical beliefs that currently guide the management of treatment-resistant depression in terms of symptoms, function, satisfaction, side-effect…”
Background
Research works printed but not linked: 9
- 10.1001%2Fjama.263.10.1385 · DOI
- 10.1176%2Fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2Fappi.ajp.163.9.1519 · DOI · Paper page
- 10.1176%2Fappi.ajp.163.9.1531 · DOI
- 10.1176%2Fappi.ajp.163.11.1905 · doi:10.1176/appi.ajp.163.11.1905 · Paper page
- 10.1176%2Fappi.ajp.164.5.739 · DOI · Paper page
- 10.1001%2Fjama.287.13.1646 · DOI
- 10.1159%2F000235736 · DOI · Paper page
- 10.1016%2FS0895-4356%2899%2900161-4 · DOI · Paper page
Cited by
Items 101–200 of 345
Clinical judgment in psychiatry. Requiem or reveille?
Fava, G. A. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2012.701665 · Cited by 38
Emmrich, A., Beesdo-Baum, K., Gloster, A. T., Knappe, S., Höfler, M., Arolt, V., Deckert, J., Gerlach, A. L., Hamm, A., Kircher, T., et al. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000335246 · Cited by 38
Investigation of age and gender effects on positive orientation in Italian twins
Fagnani, C., Medda, E., Stazi, M. A., Caprara, G. V., & Alessandri, G. (2014) · International Journal of Psychology · doi:10.1002/ijop.12053 · Cited by 41
Lunghi, C., Antonazzo, I. C., Burato, S., Raschi, E., Zoffoli, V., Forcesi, E., Sangiorgi, E., Menchetti, M., Roberge, P., & Poluzzi, E. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s241780 · Cited by 41
Depression: why drugs and electricity are not the answer
Read, J., & Moncrieff, J. (2022) · Psychological Medicine · doi:10.1017/s0033291721005031 · Cited by 43
“A subsequent analysis found that only 108 participants out of a total of over 4000 recovered, remained well and completed the study, a figure that is still based on the secondary outcome (Pigott et al., 2010).”
Costa-Nunes, J. P., Cline, B. H., Araújo-Correia, M., Valença, A., Васильева, Н. А., Dolgov, O., Kubatiev, A. A., Yeritsyan, N., Steinbusch, H. W. M., & Strekalova, T. V. (2015) · BioMed Research International · doi:10.1155/2015/596126 · Cited by 37
Treatment Selection in Depression: The Role of Clinical Judgment
Tomba, E., & Fava, G. A. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.003 · Cited by 35
Mental health self-management questionnaire: Development and psychometric properties
Coulombe, S., Radziszewski, S., Trépanier, S., Provencher, H. L., Roberge, P., Hudon, C., Meunier, S., Provencher, M. D., & Houle, J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.007 · Cited by 37
Horowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000080 · Cited by 33
Bet, P. M., Hugtenburg, J. G., Penninx, B. W. J. H., van Balkom, A. J. L. M., Nolen, W. A., & Hoogendijk, W. J. G. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.06.023 · Cited by 36
“BAI scores were used to categorise anxiety disorders: mild (0-21), moderate (22-35) and severe disorder (36-63).”
STAR*D: A Tale and Trail of Bias
Pigott, H. E. (2011) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.13.1.6 · Cited by 31
Self-citationFrӧhlich, F., & Townsend, L. (2021) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-021-00227-8 · Cited by 42
Stotland, N. L. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.007 · Cited by 30
Shao, J., Qin, J., Wang, H., Sun, Y., Zhang, W., Wang, X., Wang, T., Li, X., Yao, Z., & Lü, Q. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.08.005 · Cited by 31
The Ethics of Clinical Trials Research in Severe Mood Disorders
Nugent, A. C., Miller, F. G., Henter, I. D., & Zarate, C. A. (2017) · Bioethics · doi:10.1111/bioe.12349 · Cited by 30
Cosci, F., & Chouinard, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00007-x · Cited by 41
Arnold, M. M., Müller-Oerlinghausen, B., Hemrich, N., & Bönsch, D. (2020) · Brain Sciences · doi:10.3390/brainsci10100676 · Cited by 33
Strekalova, T. V., Anthony, D. C., Dolgov, O., Anokhin, K. V., Kubatiev, A. A., Steinbusch, H. W. M., & Schroeter, C. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.02.015 · Cited by 37
Steidtmann, D. K., Manber, R., Blasey, C. M., Markowitz, J. C., Klein, D. N., ROTHBAUM, B. O., Thase, M. E., Kocsis, J. H., & Arnow, B. A. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0033250 · Cited by 29
Cronin, C. J., Forsstrom, M. P., & Papageorge, N. (2020) · National Bureau of Economic Research · doi:10.3386/w27711 · Cited by 41
Effects of body-oriented yoga: a RCT study for patients with major depressive disorder
Bieber, M., Görgülü, E., Schmidt, D., Zabel, K., Etyemez, S., Friedrichs, B., Prvulovic, D., Reif, A., & Oertel, V. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01277-5 · Cited by 27
Principles of Psychosomatic Assessment
Fava, G. A., Sonino, N., & Wise, T. N. (2011) · Advances in psychosomatic medicine · doi:10.1159/000329997 · Cited by 32
Bowrey, H. E., James, M. H., & Aston‐Jones, G. (2017) · Depression and Anxiety · doi:10.1002/da.22635 · Cited by 26
Lucire, & Crotty, C. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s17445 · Cited by 29
Sawada, N., Uchida, H., Watanabe, K., Kikuchi, T., Suzuki, T., Kashima, H., & Mimura, M. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07078 · Cited by 26
“Pigott et al 15 reanalyzed the data from STAR * D and found that the results of STAR * D may be even worse than previously appreciated.”
Dekker, J., Van, H. L., Hendriksen, M., Koelen, J. A., Schoevers, R. A., Kool, S., van Aalst, G., & Peen, J. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341177 · Cited by 30
“However, the HAM-D does not differentiate between core depression symptoms – such as mood, anhedonia or suicidal thoughts – and accessory symptoms like lack of appetite or sleeping problems [61–64] .”
BackgroundPoorer Long-Term Outcomes among Persons with Major Depressive Disorder Treated with Medication
Vittengl, J. R. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000479162 · Cited by 26
“Nonetheless, active treatments including antidepressant medication or cognitive therapy reduce depressive symptoms and delay relapse compared to inactive controls [2–4] .”
Kirsch, I., Huedo-Medina, T. B., Pigott, H. E., & Johnson, B. T. (2018) · Psychology of Consciousness: Theory, Research, and Practice · doi:10.1037/cns0000164 · Cited by 24
Self-citationRiesenberg, R. A., Yeung, P. P., Rekeda, L., Sachs, G. S., Kerolous, M., & Fava, M. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14643 · Cited by 30
The Brain Effects of Laser Acupuncture in Depressed Individuals: An fMRI Investigation
Quah‐Smith, I., Wen, W. X., Chen, X., Williams, M., & Sachdev, P. S. (2012) · Medical Acupuncture · doi:10.1089/acu.2011.0870 · Cited by 25
Hengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
Carroll, B. J. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00972.x · Cited by 26
“We have lately heard a drumbeat of doubt concerning the value of antidepressant drugs, which some say are hardly superior to placebo (1, 2).”
A randomized controlled trial of an HIV/AIDS Symptom Management Manual for depressive symptoms
Eller, L. S., Kirksey, K. M., Nicholas, P. K., Corless, I. B., Holzemer, W. L., Wantland, D. J., Willard, S. S., Robinson, L. A., Hamilton, M. J., Sefcik, E. F., et al. (2012) · AIDS Care · doi:10.1080/09540121.2012.712662 · Cited by 24
“This is supported by a meta-analysis questioning the effectiveness of antidepressants (Pigott, Leventhal, Alter, & Boren, 2010 ).”
ResultPolypharmacy or medication washout: an old tool revisited
Hoffman, D., Schiller, M. J., Greenblatt, J. M., & Iosifescu, D. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s24375 · Cited by 21
The antidepressant standoff: Why it continues and how to resolve it
Ormel, J., Spinhoven, P., de Vries, Y. A., Cramer, A. O. J., Siegle, G. J., Bockting, C. L. H., & Hollon, S. D. (2020) · Psychological Medicine · doi:10.1017/s0033291719003295 · Cited by 22
“This is a serious limitation as about half do not remit on acute phase treatment (Khin, Chen, Yang, Yang, & Laughren, 2011; Levkovitz et al., 2011; Pigott, Leventhal, Alter, & Boren, 2010; Rush et al., 2006).”
Post hoc decision-making in observational epidemiology—is there need for better research standards?
Kivimäki, M., Singh‐Manoux, A., Ferrie, J. E., & Batty, G. D. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt036 · Cited by 25
Sex and hormonal status influence the anxiolytic-like effect of oxytocin in mice
Nisbett, K. E., Gonzalez, L. A., Teruel, M., Carter, C. S., Vendruscolo, L. F., Ragozzino, M. E., & Koob, G. F. (2023) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100567 · Cited by 24
Meta-Analysis, Ideals of Objectivity, and the Reliability of Medical Knowledge
Jukola, S. (2015) · Science & Technology Studies · doi:10.23987/sts.55344 · Cited by 24
“Analyses “document a profound publication bias that inflates [SSRIs’] apparent efficacy” (Pigott et al., 2010: 267).”
BackgroundResultInfluentialIncreased use of ketamine for the treatment of depression: Benefits and concerns
Na, K., & Kim, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110060 · Cited by 26
The network analysis of depressive symptoms before and after two weeks of antidepressant treatment
Zhou, J. L., Liu, S., Mayes, T. L., Feng, Y., Fang, M., Xiao, L., & Wang, G. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.059 · Cited by 25
Cannabidiol Modulates Alterations in PFC microRNAs in a Rat Model of Depression
Bright, U., & Akirav, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032052 · Cited by 22
“Antidepressants are the current recommended standard of treatment for depression; however, their effectiveness is only slightly efficacious compared to placebos [2].”
BackgroundPhysical activity as a treatment for depression: the TREAD randomised trial protocol
Baxter, H., Winder, R., Chalder, M., Wright, C., Sherlock, S., Haase, A., Wiles, N. J., Montgomery, A. A., Taylor, A. H., Fox, K. R., et al. (2010) · Trials · doi:10.1186/1745-6215-11-105 · Cited by 21
“Whilst antidepressants are the most commonly prescribed treatment for depression, there is concern about their use and effectiveness, especially in mild/moderate cases [6-8].”
BackgroundSiwek, M., Gorostowicz, A., Chrobak, A. A., Gerlich, A., Krupa, A. J., Juryk, A., & Dudek, D. (2023) · Brain Sciences · doi:10.3390/brainsci13010086 · Cited by 20
“Unfortunately, the effectiveness of pharmacotherapy in the treatment of depression is far from satisfying [4].”
BackgroundPréville, M., Vasiliadis, H.-M., Bossé, C., Dionne, P.-A., Voyer, P., Brassard, J., & Scientific Committee of the ESA Study (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600606 · Cited by 20
Schlicker, S., Weisel, K. K., Buntrock, C., Berking, M., Nobis, S., Lehr, D., Baumeister, H., Snoek, F. J., Riper, H. M., & Ebert, D. D. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2634094 · Cited by 20
“Despite the well-proven effectiveness of pharmacological antidepressant treatment [48, 49], side effects can be considerably high.”
BackgroundXu, Z., Xie, C., Xia, L., Yuan, Y., Zhu, H., Huang, X., Li, C., Yu, T., Qu, X., Zhang, F., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0689-x · Cited by 20
The involvement of GABAergic system in the antidepressant-like effect of agmatine
Neis, V. B., Rosado, A. F., Olescowicz, G., Moretti, M., da Rosa, P. B., Platt, N., & Rodrigues, A. L. S. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01910-5 · Cited by 22
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine
Wilkowska, A., & Cubała, W. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314605 · Cited by 22
Nguyen, B., Weiss, P., Beydoun, H. A., & Kancherla, V. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.019 · Cited by 20
Conséquences de l’inter-relation des systèmes monoaminergiques dans l’activité antidépressive
Tritschler, L., Gaillard, R., Gardier, A. M., David, D. J. P., & Guilloux, J. (2018) · L Encéphale · doi:10.1016/j.encep.2018.05.001 · Cited by 21
“[111] Pigott HE, Leventhal AM, Alter GS, et al.”
BackgroundWhat does the latest meta-analysis really tell us about antidepressants?
Moncrieff, J. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000240 · Cited by 24
“In the large longitudinal STAR-D study, the proportion of people who adhered to recommended treatment, recovered and did not relapse was startlingly low (only 108 out of the 3110 people who satisfied inclusion criteria) (Pigott et al. 2010).”
BackgroundThe American Psychiatric Association’s Guideline for Major Depressive Disorder: A Commentary
Cosgrove, L., Shaughnessy, A. F., Wheeler, E. E., Austad, K., Kirsch, I., & Bursztajn, H. J. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000335523 · Cited by 19
“Thus, the reader is left with the erroneous impression [6, 7] that there is a clear evidence base for generally recommending the use of ADs as the initial treatment for mild to moderate depression, and ADs work even more effectively for severe depression.”
BackgroundSullivan, M. J. L., Adams, H., Yamada, K., Kubota, Y., Ellis, T., & Thibault, P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.129 · Cited by 18
On ideals of objectivity, judgments, and bias in medical research – A comment on Stegenga
Jukola, S. (2017) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2017.02.001 · Cited by 27
Presentation of benefits and harms of antidepressants on websites: A cross-sectional study
Demasi, M., & Gøtzsche, P. C. (2020) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-191023 · Cited by 22
“There is no evidence for their benefit in the long term [17,18].”
BackgroundHammond, D. C. (2011) · Journal of Neurotherapy · doi:10.1080/10874208.2011.570694 · Cited by 23
“Even the largest and most elaborate, $35 million antidepressant study (STAR*D) found antidepressants to be only marginally efficacious compared to placebos (and without controlling for publication bias; Pigott, Leventhal, Alter, & Boren, 2009 ).”
BackgroundHengartner, M. P., Passalacqua, S., Andreae, A., Heinsius, T., Hepp, U., Rössler, W., & von Wyl, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00079 · Cited by 20
Early Life Adversity and Risk for Depression
Pagliaccio, D., & Barch, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802456-0.00002-9 · Cited by 17
Vasiliadis, H.-M., Latimer, E., Dionne, P.-A., & Préville, M. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800405 · Cited by 17
Geng, L., Ye, D., Shi, Y., Xu, Z., Pu, M., Li, Z., Li, X., Li, Y., & Zhang, Z. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12201 · Cited by 20
“Up to now, the poor response and individual variation in drug response are major limitations of current antidepressant treatment [1].”
BackgroundIatrogenia y prevención cuaternaria en salud mental
Lobo, A. O., & Rojo, V. (2011) · Revista Española de Salud Pública · doi:10.1590/s1135-57272011000600002 · Cited by 50
Norbury, A., & Seymour, B. (2018) · F1000Research · doi:10.12688/f1000research.13723.2 · Cited by 18
Psychiatry’s Continuing Expansion of Depressive Disorder
Wakefield, J. C., & Horwitz, A. V. (2015) · History, philosophy and theory of the life sciences · doi:10.1007/978-94-017-7423-9_12 · Cited by 19
Mischoulon, D. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11com07463 · Cited by 19
Núñez, C., Delgadillo, J., Barkham, M., & Behn, A. J. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1756 · Cited by 17
“This is a problem, considering that researchers have been attempting to find associations between different symptoms of depression and distinct risk factors [29, 30], different gene polymorphisms [31], and different responses to treat-ment [32, 33].”
Psychiatry Under the Influence
Whitaker, R. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-44911-1_7 · Cited by 15
Hancu, G., Uilăcan, A., & Blebea, N. M. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3040037 · Cited by 16
“In some cases, mood stabilizers, antipsychotics, or anxiolytic medications may be used alongside classic antidepressants [10,11].”
Lapierre, J. L., Kosenko, P. O., Kodama, T., Peever, J. H., Mukhametov, L. M., Lyamin, O. I., & Siegel, J. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2603-12.2013 · Cited by 15
“Some recent work has concluded that the mood-elevating effects of SSRIs is no greater than those of a placebo (Kirsch, 2009; Pigott et al., 2010).”
BackgroundZiemichód, W., Kurowska, A., Grabowska, K., Kurowska, M., & Biała, G. (2023) · Molecules · doi:10.3390/molecules28083575 · Cited by 19
“A 2010 review of the literature suggests that antidepressants are only marginally efficacious compared to placebos and documents profound publication bias that inflates their apparent efficacy, according to the FDA, indicating the need for a reappraisal of the current standard care for depressive disorders [16].”
BackgroundUncoupling the Dopamine D1–D2 Receptor Complex: A Novel Target for Antidepressant Treatment
Wong, A. H. C., & Liu, F. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.311 · Cited by 15
Network meta-analysis of antidepressants
Timimi, S. B., Moncrieff, J., Gøtzche, P. C., Davies, J., Kinderman, P., Byng, R., Montagu, L., & Read, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31784-7 · Cited by 14
Stassen, H. H., Bachmann, S., Bridler, R., Cattapan, K., Herzig, D., Schneeberger, A. R., & Seifritz, E. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01169-0 · Cited by 16
The Commercialization of Research and the Quest for the Objectivity of Science
Jukola, S. (2014) · Foundations of Science · doi:10.1007/s10699-014-9377-8 · Cited by 18
Is suicide a mental health, public health or societal problem?
Goel, D., Dennis, B. R., & McKenzie, S. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000888 · Cited by 15
Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients
Breggin, P. R. (2015) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-015-9307-2 · Cited by 16
Gaudiano, B. A., Hughes, J. A., & Miller, I. W. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.06.003 · Cited by 16
“Results from the recent STAR*D study showed that antidepressant efficacy in routine clinical practice was lower than in clinical trials [26].”
ResultTraditional Herbal Medicine, Pharmacognosy, and Pharmacopoeial Standards
Roy Upton, R. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800874-4.00003-9 · Cited by 26
Thase, M. E., Yeung, P. P., Rekeda, L., Liu, M., & Varughese, S. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000528 · Cited by 14
Chronic venlafaxine treatment fails to alter the levels of galanin system transcripts in normal rats
Petschner, P., Juhász, G., Tamási, V., Ádori, C., Tóthfalusi, L., Hökfelt, T. G. M., & Bagdy, G. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.01.010 · Cited by 13
“, 2006), they cannot always prevent further depressive episodes (Pigott et al., 2010; Trivedi et al., 2006) and they have a delay in the onset of their therapeutic effect (Gex-Fabry et al.”
BackgroundPredicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care
Liberman, J. N., Davis, T., Pesa, J., Chow, W., Verbanac, J., Heverly-Fitt, S., & Ruetsch, C. R. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.8.987 · Cited by 12
Effects of chronic fluoxetine treatment on anxious behaviour of BALB/c mice in a 3-dimensional maze
Abuhamdah, R. M. A., Hussain, M. D., Chazot, P. L., & Ennaceur, A. (2015) · Stress · doi:10.3109/10253890.2015.1083550 · Cited by 13
McPherson, S., & Hengartner, M. P. (2019) · BJPsych Open · doi:10.1192/bjo.2019.65 · Cited by 15
Nugent, A. C., Iadarola, N. D., Miller, F. G., Luckenbaugh, D. A., & Zarate, C. A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00006-7 · Cited by 11
Zaninotto, L., Souery, D., Calati, R., Sentissi, O., Kasper, S. F., Akimova, E., Zohar, J., Montgomery, S., Mendlewicz, J., & Serretti, A. (2013) · Annals of Clinical Psychiatry · doi:10.1177/104012371302500204 · Cited by 14
Edlund, M. J., Pettiford, A. G., Hampton, J. C., Forman‐Hoffman, V. L., Ault, K. L., Colpe, L. J., & Hedden, S. L. (2015) · Psychiatric Services · doi:10.1176/appi.ps.201400018 · Cited by 12
Psychotherapy and Pharmacotherapy: A Contemporary Perspective
Sandberg, L. S., & Busch, F. N. (2012) · Psychodynamic Psychiatry · doi:10.1521/pdps.2012.40.3.505 · Cited by 12
Evidence-Based Somatic Treatment of Depression in Adults
Carlat, D. J. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.002 · Cited by 13
Jiang, D., Jiang, S., Gong, F., Yuan, F., Zhao, P., He, X., Lv, G., & Chu, X. (2018) · The American Surgeon · doi:10.1177/000313481808400851 · Cited by 12
False Beliefs in Academic Psychiatry: The Case of Antidepressant Drugs
Hengartner, M. P., & Plöderl, M. (2018) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.20.1.6 · Cited by 10
“Research further suggests that this small effect size is inflated due to conflicts of interest and method biases and that it is clinically insignificant in routine practice (Gotzsche, 2015; Hengartner, 2017; Moncrieff & Kirsch, 2005; Pigott et al., 2010).”
BackgroundInfluentialGhalavand, R., Ghafuri, H., & Ardeshiri, H. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-58563-0 · Cited by 10
“Furthermore, benzodiazepine derivatives have found wide-ranging use due to their therapeutic properties, such as anticonvulsants 28 , sedatives 29 , and antidepressants 30 .”
BackgroundAntidepressant drug use and future diabetes risk
Kivimäki, M., & Batty, G. D. (2011) · Diabetologia · doi:10.1007/s00125-011-2360-9 · Cited by 11
“The authors of the review noticed that in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, the largest antidepressant effectiveness trial ever conducted, there was an apparent progressively increasing dropout rate across each study phase [7].”
Li, X., Shao, J., Wang, H., Wang, X., Zhu, R., Yao, Z., & Lü, Q. (2022) · European Radiology · doi:10.1007/s00330-022-09004-x · Cited by 10
“However, despite following these gold standards, approximately 50% of MDDs cannot respond to the first-line antidepressants [3].”
BackgroundInfluentialThe politics of knowledge: implications for understanding and addressing mental health and illness
Jenkins, E. (2013) · Nursing Inquiry · doi:10.1111/nin.12026 · Cited by 14
Treatment outcome variation between depression symptom combinations in the STAR*D study
Olbert, C. M., Rasmussen, A., Gala, G. J., & Tupler, L. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.050 · Cited by 12
Beckmann, F., Seidenbecher, S., Metzger, C. D., Gescher, D. M., Carballedo, A., Tozzi, L., O’Keane, V., & Frodl, T. (2022) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2022.111440 · Cited by 11
L'approche transdiagnostique en psychopathologie
der Linden, M. V. (2016) · Dunod eBooks · doi:10.3917/dunod.mones.2016.01.0009 · Cited by 15
Atkins, B., Maden, M., Birt, L., Tromans, S. J., Swithenbank, Z., Kersey, O. R., Smith, P. A., & Scott, S. (2025) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2025.02.004 · Cited by 13
Scheepens, D. S., van Waarde, J. A., ten Doesschate, F., Westra, M., Kroes, M. C. W., Schene, A. H., Bockting, C., Schoevers, R. A., Denys, D. A. J. P., Ruhé, H. G., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12389 · Cited by 12
Beydoun, H. A., Beydoun, M. A., Wassertheil-Smoller, S. W., Saquib, N., Manson, J. E., Snetselaar, L., Weiss, J., Zonderman, A. B., & Brunner, R. L. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02872-5 · Cited by 9
Samaan, Z., Litke, K., McCabe, K., Dennis, B. B., Whattam, J., Garrick, L., O’Neill, L., Tabak, T. A., Simons, S., Chalmers, S. A., et al. (2015) · Pilot and Feasibility Studies · doi:10.1186/s40814-015-0034-y · Cited by 12
“7 % of patients show inadequate response to treatment [4, 5].”
Background
Metadata
- Authors
- Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J.
- Affiliations
- American University (US)
- ORCID
- Pigott, H. Edmund
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 79
- Issue
- 5
- Pages
- 267-279
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2020265264
- Cited by
- 347
- References
- 58
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 15 · 2023: 21 · 2022: 13 · 2021: 23 · 2020: 18 · 2019: 22 · 2018: 22 · 2017: 16 · 2016: 19 · 2015: 42 · 2014: 22 · 2013: 20 · 2012: 26
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, depression, antidepressant efficacy, publication bias, STAR*D trial, meta-analysis, selective outcome reporting, dropout rates
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Publication Bias, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.